"10.1371_journal.pone.0007669","plos one","2009-11-03T00:00:00Z","Christina L Roland; Kristi D Lynn; Jason E Toombs; Sean P Dineen; D Gomika Udugamasooriya; Rolf A Brekken","Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Advanced Imaging Research Center and Department of Biochemistry University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America","Conceived and designed the experiments: CLR KDL SPD RAB. Performed the experiments: CLR KDL JET. Analyzed the data: CLR RAB. Contributed reagents/materials/analysis tools: JET DGU. Wrote the paper: CLR.","R. A. Brekken is a consultant for, has equity interest in, and is a recipient of sponsored research grant from Peregrine Pharmaceuticals Inc. R. A. Brekken is also an author of a patent on technology that was used to develop the antibody r84 by Peregrine Pharmaceuticals and Affitech AS. Peregrine Pharmaceuticals supported these studies by providing r84, mcr84, and funding but did not participate in planning, execution, or interpretation of the experiments.","2009","11","Christina L Roland","CLR",6,TRUE,4,3,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
